Stoke Posts $73.6M Q3 Loss as Dravet Phase 3 Nears Readout, Cash Runs to Early 2028
STOK sits 30% above its 52-week low of $20.32.
Summary
Stoke reported a Q3 2026 net loss of $73.6 million, or $1.08 per share, versus a $38.3 million loss a year earlier, as R&D spending jumped to $59.8 million on zorevunersen Phase 3 work and launch preparation. Revenue was $11.3 million, up modestly from $10.6 million and ahead of analyst expectations on its Biogen and Acadia collaborations. The company held $358.8 million in cash and marketable securities at September 30, which it says funds operations into early 2028 — covering the expected Phase 3 EMPEROR data readout in Q3 2027 and NDA submission in the second half of 2027. Enrollment in the primary analysis population is complete at 162 patients; roughly 110 have passed the Week 28 primary endpoint and about 20 have completed Week 52 with no discontinuations. The FDA-aligned NDA plan now uses a multicomponent Vineland-3 assessment for the cognition and behavior secondary endpoint. Biogen (BIIB) is the ex-US commercialization partner on zorevunersen; the update is neutral for BIIB. The key binary event remains the Q3 2027 EMPEROR readout.
At the time of this announcement, STOK was trading at $26.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $20.32 to $40.22. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.